By Nana O 
Researchers at the Montefiore Einstein Comprehensive Cancer Center (MECCC) and Albert Einstein College of Medicine have unveiled groundbreaking findings that fundamentally alter our understanding of glioblastoma, the most aggressive and lethal form of brain cancer. Contrary to previous assumptions that glioblastoma exclusively targets brain tissue, this new research demonstrates that the disease initiates a far more widespread assault, actively damaging the skull, profoundly altering the immune cell composition within the skull’s bone marrow, and ultimately disrupting the body’s systemic immune defenses. These pivotal discoveries, published on October 3rd in the prestigious journal Nature Neuroscience, carry significant implications, suggesting that even therapeutic approaches aimed at mitigating bone loss could inadvertently accelerate the progression of this devastating illness.
A Paradigm Shift in Glioblastoma Understanding
For decades, glioblastoma has been approached as a localized malignancy confined to the brain. However, the recent work by Jinan Behnan, Ph.D., assistant professor in the Leo M. Davidoff Department of Neurological Surgery and the department of microbiology & immunology at Einstein, and a key member of the National Cancer Institute (NCI)-designated MECCC, challenges this long-held paradigm. "Our discovery that this notoriously hard-to-treat brain cancer interacts with the body’s immune system may help explain why current therapies — all of them dealing with glioblastoma as a local disease — have failed, and it will hopefully lead to better treatment strategies," stated Dr. Behnan, the paper’s corresponding author. This suggests a potential systemic component to glioblastoma that has been overlooked, opening new avenues for research and therapeutic intervention.
The stark reality of glioblastoma underscores the urgency of these findings. In the United States alone, approximately 15,000 individuals are diagnosed with glioblastoma each year, according to the NCI. The current standard of care, a multi-modal approach involving surgery, chemotherapy, and radiation, offers a grim prognosis, with a median survival time of only about 15 months. The lack of significant progress in improving these survival rates highlights the critical need for a deeper understanding of the disease’s complex biology.
The Crucial Role of Calvarial Marrow
The skull, or calvarium, is not merely a protective casing for the brain; it is a dynamic tissue that, like other bones in the body, harbors bone marrow. This marrow is a vital factory for producing immune cells and other essential blood components. Dr. Behnan’s team was particularly inspired by emerging research that had identified extremely fine channels connecting the skull to the brain. These intricate pathways were known to facilitate the exchange of molecules and immune cells, hinting at a potential bidirectional communication network.
Leveraging sophisticated imaging technologies, the researchers meticulously studied mice that had developed two distinct types of glioblastoma. Their observations revealed a disturbing pattern: the tumors induced significant erosion of the skull bones, with the most pronounced damage occurring along the sutures, the fibrous joints where the skull bones fuse. Crucially, this specific type of bone loss was found to be exclusive to glioblastoma and other aggressive brain tumors. It was conspicuously absent in control groups of mice that had experienced strokes, other forms of brain injury, or cancers located elsewhere in the body. To validate these findings in humans, the team analyzed CT scans of patients diagnosed with glioblastoma. The scans mirrored the mouse model, revealing comparable reductions in skull thickness in the same anatomical regions where bone erosion was observed in the animal subjects.
Enlarged Channels: A Gateway for Immune Disruption
The erosion of skull bone, as observed in the mouse models, led to a significant increase in both the number and the size of the channels that bridge the skull and the brain. The scientists hypothesized that these augmented conduits could serve as a direct route for the glioblastoma tumor to disseminate molecular signals into the skull marrow. These signals, they proposed, would then exert a profound influence on the marrow’s immune microenvironment.
A Pro-Inflammatory Shift in the Skull Marrow’s Immune Landscape
To investigate the immunological consequences of this tumor-induced bone erosion and channel enlargement, the researchers employed single-cell RNA sequencing, a cutting-edge technology that allows for the detailed analysis of gene expression in individual cells. The results were striking: glioblastoma had dramatically rewired the immune cell balance within the skull marrow. The cancer instigated a pronounced shift favoring pro-inflammatory myeloid cells. Specifically, the levels of inflammatory neutrophils nearly doubled, while several types of antibody-producing B cells, along with other B cell populations, were almost entirely eradicated.
"The skull-to-brain channels allow an influx of these numerous pro-inflammatory cells from the skull marrow to the tumor, rendering the glioblastoma increasingly aggressive and, all too often, untreatable," explained E. Richard Stanley, Ph.D., a professor of developmental and molecular biology at Einstein and a co-author of the study. This finding is particularly significant as it suggests a mechanism by which the tumor can actively recruit immune cells that, rather than fighting the cancer, promote its growth and aggression. Dr. Stanley further elaborated on the therapeutic implications: "This indicates the need for treatments that restore the normal balance of immune cells in the skull marrow of people with glioblastoma. One strategy would be suppressing the production of pro-inflammatory neutrophils and monocytes while at the same time restoring the production of T and B cells."
Systemic Impact: Skull Marrow vs. Femur Marrow
Further underscoring the systemic nature of glioblastoma’s influence, the study revealed differential responses between the skull marrow and the marrow of a long bone, the femur. While glioblastoma actively activated several genes in the skull marrow that amplified the production of inflammatory immune cells, the cancer had the opposite effect on femur marrow. In the femur, the tumor suppressed genes essential for the production of various types of immune cells, highlighting a complex and site-specific immune modulation orchestrated by the brain tumor. This divergence in immune response between different bone marrow sites further strengthens the argument that glioblastoma is not merely a local brain disease but a systemic one with far-reaching consequences.
Unintended Consequences of Osteoporosis Medications
Intrigued by the role of bone erosion, the researchers explored the potential impact of anti-osteoporosis drugs, which are designed to prevent bone loss. They administered two U.S. Food and Drug Administration-approved osteoporosis medications, zoledronic acid and denosumab, to mice with glioblastoma tumors. Both drugs effectively halted skull bone erosion. However, a concerning observation emerged: zoledronic acid, in one type of glioblastoma model, actually accelerated tumor progression. Furthermore, both osteoporosis drugs interfered with the efficacy of anti-PD-L1, an immunotherapy drug known to enhance the activity of tumor-fighting T cells. This finding is critical, as it suggests that common treatments for bone health could potentially have detrimental effects on glioblastoma patients, underscoring the need for careful consideration and further investigation before such interventions are used in this patient population.
Broader Implications and Future Directions
The implications of this research are vast and promise to reshape the landscape of glioblastoma treatment. By revealing the intricate interplay between glioblastoma, skull bone integrity, and the bone marrow immune microenvironment, the study provides a compelling explanation for the historical failures of current therapeutic strategies. The current treatments, focused solely on the tumor within the brain, have failed to account for these systemic immune alterations.
The findings strongly suggest that future therapeutic strategies must adopt a more holistic approach, targeting not only the tumor itself but also the disrupted immune environment within the skull marrow. Potential avenues include developing therapies that can re-establish a balanced immune cell population in the skull marrow, perhaps by selectively inhibiting pro-inflammatory cell production while simultaneously bolstering the generation of anti-tumor immune cells like T and B lymphocytes.
The discovery also raises critical questions about the safety of common medications in the context of glioblastoma. The adverse effects observed with osteoporosis drugs highlight the urgent need for comprehensive preclinical and clinical studies to evaluate potential drug interactions and contraindications for glioblastoma patients.
The MECCC and Einstein researchers, alongside their collaborators at Osaka University (Japan), Karolinska Hospital (Sweden), Duke University Medical Center (USA), University of California, San Francisco (USA), and the German Rheumatism Research Center (Germany), have laid the groundwork for a new era of glioblastoma research. The paper, titled "Brain Tumors Induce Widespread Disruption of Calvarial Bone and Alteration of Skull Marrow Immune Landscape," represents a significant leap forward in understanding this complex and devastating disease. The collaborative effort involved a multidisciplinary team, including Abhishek Dubey, Biljana Stangeland, Imane Abbas, David Fooksman, Ph.D., Wade R. Koba, B.S., Jinghang Zhang, M.D., Benjamin T. Himes, Ph.D., Derek Huffman, Ph.D., Zhiping Wu, Rachel Welch, David Reynolds, B.S., Kostantin Dobrenis, Ph.D., Qinge Ye, Kevin Fisher, and Emad Eskandar, M.D., from MECCC and Einstein, alongside Erika Yamashita, Yutaka Uchida, and Masaru Ishii from Osaka University, Robert A. Harris from Karolinska Hospital, Gregory M. Palmer from Duke University Medical Center, Olivia R. Lu and Winson S. Ho from the University of California, San Francisco, and Alexander F. Fiedler from the German Rheumatism Research Center and Freie Universität Berlin.
This extensive collaboration underscores the global effort to combat glioblastoma and the interconnectedness of scientific inquiry across continents. The findings are expected to ignite further research into the systemic effects of brain tumors and pave the way for the development of more effective and targeted therapies for patients battling this formidable cancer. The journey towards overcoming glioblastoma is arduous, but this recent breakthrough offers a beacon of hope, illuminating a path toward a more comprehensive and effective treatment paradigm.
